| 靶点: |
EC50: 398 nM (S1PR1). |
| 体内研究: |
W146 TFA (5 mg/kg,腹腔注射,在 AMD3100 给药之前) 预处理显示,与单独使用 AMD3100 处理的小鼠相比,通过 CFU-G/M 集落形成测定测量,KSL-HSPC 动员增加约 8 倍。 W146 TFA 介导的 KSL-HSPC 动员增强是特异性的,因为用 W140 预处理小鼠不能对 AMD3100 刺激的 KSL-HSPC 动员产生任何影响。注射 W146、W140、JTE013 或 Cay10444 不会改变小鼠的基础 WBC 计数。 |
| 参考文献: |
1. M Germana Sanna, et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol. 2006 Aug;2(8):434-41. Epub 2006 Jul 9. 2. Jingjing Liu, et al. 3-amino-4-(3-hexylphenylamino)-4-oxobutyl phosphonic acid (W146), a Selective Antagonist of Sphingosine-1-phospahte Receptor Subtype 1, Enhances AMD3100-stimulated Mobilization of Hematopoietic Stem Progenitor Cells in Animals. J Biochem Pharmacol Res. 2013 Dec; 1(4): 197–203. 3. Hang Wang, et al. Sphingosine-1-phosphate promotes the proliferation and attenuates apoptosis of Endothelial progenitor cells via S1PR1/S1PR3/PI3K/Akt pathway. Cell Biol Int. 2018 May 23. |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.191 ml |
10.955 ml |
21.911 ml |
| 5 mM |
0.438 ml |
2.191 ml |
4.382 ml |
| 10 mM |
0.219 ml |
1.096 ml |
2.191 ml |
| 50 mM |
0.044 ml |
0.219 ml |
0.438 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |